Supercharged immune cells take on Hard-to-Treat cancers
NCT ID NCT07349160
First seen Jan 18, 2026 · Last updated Apr 30, 2026 · Updated 19 times
Summary
This early-phase study tests a new treatment called Meta10-TIL for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in the lab to better fight cancer. The main goal is to check safety, and researchers will also see if tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, 100000, China
Contact
Contact
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.